NEW YORK (TheStreet) -- InterMune (ITMN) shares continue to climb on heavy volume Tuesday, up 0.2% to $73, after the company agreed to be bought by Swiss pharmaceutical company Roche for $8.3 billion.

See what Jim Cramer thinks of Roche's bid for InterMune:


WATCH: More market update videos on TheStreet TV | More videos from Jim Cramer

More than 12.5 million shares have been traded so far today, more than six times its three-month daily average.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ITMN data by YCharts

Image placeholder title

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.